http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#Head http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#assertion http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#provenance http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#pubinfo http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#assertion http://purl.obolibrary.org/obo/DOID_12384 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_12384 http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00537 http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association http://www.w3.org/2000/01/rdf-schema#label ciprofloxacin tablets usp are indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below ciprofloxacin is a fluoroquinolone antibacterial indicated in adults 18 years of age with infections caused by designated susceptible bacteria and in pediatric patients where indicated 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 1 1 1 11 1 12 1 13 1 14 1 16 ciprofloxacin tablets are indicated in adult patients for treatment of urinary tract infections caused by escherichia coli klebsiella pneumoniae enterobacter cloacae serratia marcescens proteus mirabilis providencia rettgeri morganella morganii citrobacter koseri citrobacter freundii pseudomonas aeruginosa staphylococcus epidermidis staphylococcus saprophyticus enterococcus faecalis ciprofloxacin tablets are indicated in adult female patients for treatment of acute uncomplicated cystitis caused by escherichia coli staphylococcus saprophyticus ciprofloxacin tablets are indicated in adult patients for treatment of chronic bacterial prostatitis caused by escherichia coli proteus mirabilis ciprofloxacin tablets are indicated in adult patients for treatment of lower respiratory tract infections caused by escherichia coli klebsiella pneumoniae enterobacter cloacae proteus mirabilis pseudomonas aeruginosa haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis see indications and usage 1 15 ciprofloxacin tablets are indicated in adult patients for treatment of acute sinusitis caused by haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli klebsiella pneumoniae enterobacter cloacae proteus mirabilis proteus vulgaris providencia stuartii morganella morganii citrobacter freundii pseudomonas aeruginosa staphylococcus aureus staphylococcus epidermidis streptococcus pyogenes ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae serratia marcescens pseudomonas aeruginosa ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra abdominal infections used in combination with metronidazole caused by escherichia coli pseudomonas aeruginosa proteus mirabilis klebsiella pneumoniae bacteroides fragilis ciprofloxacin tablets are indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli campylobacter jejuni shigella boydii shigella dysenteriae shigella flexneri shigella sonnei ciprofloxacin tablets are indicated in adult patients for treatment of typhoid fever enteric fever caused by salmonella typhi ciprofloxacin tablets are indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to neisseria gonorrhoeae see warnings and precautions 5 16 ciprofloxacin tablets are indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections cuti and pyelonephritis due to escherichia coli see indications and usage 1 15 use in specific populations 8 4 ciprofloxacin tablets are indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax post exposure to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication 1 see clinical studies 14 2 ciprofloxacin tablets are indicated for treatment of plague including pneumonic and septicemic plague due to yersinia pestis y pestis see clinical studies 14 3 although effective in clinical trials ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls including events related to joints and or surrounding tissues see warnings and precautions 5 11 adverse reactions 6 1 use in specific populations 8 4 nonclinical toxicology 13 2 ciprofloxacin tablets are not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to streptococcus pneumoniae see indications and usage 1 4 to reduce the development of drug resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy if anaerobic organisms are suspected of contributing to the infection appropriate therapy should be administered appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin therapy with ciprofloxacin tablets may be initiated before results of these tests are known once results become available appropriate therapy should be continued as with other drugs some isolates of pseudomonas aeruginosa http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00537 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#provenance http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#pubinfo http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#sig http://purl.org/nanopub/x/hasSignature LVDTaFQZ4sUjPzzhDdYMk+2WRpY2SIDE/o7uZmWJTsrFbCroUdZHtXlFTn3sy9HfzreuFa8r8Vp3R7ywO6XFsoiYazCW1v4RGuiNJS78NrCJ9EovLN79cfvH94J5IDXC0m5eLqhtsCT6XNC1t3YQAAsV/RrlQJ/pIBRKfmbMhro= http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://purl.org/dc/terms/created 2021-06-18T08:48:54.322+02:00 http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAcN6ZI0b3wGFVj5mnFihnUAE1Yt-q-EormnXQdLoSMoQ https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs